THC

One Step Marijuana Test Device Package Insert

A rapid, one step test for the qualitative detection of THC metabolites in human urine.

For healthcare professionals including professionals at point of care sites

For in vitro diagnostic use only.

INTENDED USE

The THC One Step Marijuana Test Device is a rapid chromatographic immunoassay for the detection of 11-nor- $\Delta 9$ -THC-9 COOH (THC metabolite) in human urine at a cut-off concentration of 50 ng/mL.

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

SUMMARY

THC (Δ^9 -tetrahydrocannabinol) is the primary active ingredient in cannabinoids (marijuana). When smoked or orally administered, it produces euphoric effects. Users have impaired short-term memory and slowed learning. Users may also experience transient episodes of confusion and anxiety. Long term relatively heavy use may be associated with behavioral disorders. The peak effect of smoking marijuana occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is 11-nor- Δ^9 -tetrahydrocannabinol-9-carboxylic acid (Δ^9 -THC-COOH).

The THC One Step Marijuana Test Device is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of marijuana in urine. The THC One Step Marijuana Test Device yields a positive result when the concentration of marijuana in urine exceeds 50 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

PRINCIPLE

The THC One Step Marijuana Test Device is a rapid chromatographic immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody. During testing, a urine specimen migrates upward by capillary action. Marijuana, if present in the urine specimen below 50 ng/mL, will not saturate the binding sites of the antibody coated particles in the test device. The antibody coated particles will then be captured by immobilized marijuana conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the marijuana level is above 50 ng/mL because it will saturate all the binding sites of anti-marijuana antibodies.

A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control line region if the test has been performed properly.

REAGENTS

The test device contains mouse monoclonal anti-Marijuana antibody-coupled particles and Marijuana-protein conjugate. A goat antibody is employed in the control line system.

PRECAUTIONS

- For healthcare professionals including professionals at point of care sites.
- For *in vitro* diagnostic use only. Do not use after the expiration date.
- The test device should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The test strip should be discarded according to federal, state and local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C. The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing.

MATERIALS

Materials Provided

- Test devices
- Disposable specimen droppers
- Package insert


Materials Required But Not Provided

- Specimen collection container
- Timer
- External controls

DIRECTIONS FOR USE

Allow the test device, urine specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

- 1. Bring the pouch to room temperature before opening it. Remove the test device from the sealed pouch and use it as soon as possible.
- 2. Place the test device on a clean and level surface. Hold the dropper vertically and transfer 3 full drops of urine (approx. 100µl) to the specimen well (S) of the test device, and then start the timer. Avoid trapping air bubbles in the specimen well (S). See the illustration above.
- 3. Wait for the red line(s) to appear. The result should be read at 5 minutes. It is important that the background is clear before the result is read. Do not interpret the result after 10 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

NEGATIVE:* Two lines appear. One red line should be in the control region (C), and another apparent red or pink line should be in the test region (T). This negative result indicates that the marijuana concentration is below the detectable level of 50 ng/mL.

* NOTE: The shade of red in the test region (T) may vary, but it should be considered negative whenever there is even a faint pink line.

POSITIVE: One red line appears in the control region (C). No line appears in the test region (T). This positive result indicates that the marijuana concentration is above the detectable level of 50 ng/mL.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique. A clear background is also required.

Control standards are not supplied with this kit; however it is recommended that positive and negative controls be tested as good laboratory testing practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

- 1. The THC One Step Marijuana Test Device provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) are the preferred confirmatory methods.^{1,2}
- 2. It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A Positive Result does not indicate level or intoxication, administration route or concentration in urine.
- A Negative Result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cutoff level of the test
- 6. Test does not distinguish between drugs of abuse and certain medications.

PERFORMANCE CHARACTERISTICS

Accuracy

A three way side-by-side comparison was conducted using the THC One Step Marijuana Test Device and a leading commercially available THC rapid test. Testing was performed on specimens previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS. The following results were tabulated:

Method THC One Results		Other THC Rapid Test		Total
		Positive	Negative	Results
Step	Positive	143	0	143
Test Device	Negative	0	157	157
Total Results		143	157	300

Total Agreement: 100%

When compared to GC/MS at 50 ng/mL, the following results were tabulated:

Method		GC/MS		Total	
THC One	Results	Positive	Negative	Results	
Step	Positive	119	24	143	
Test Device	Negative	3	154	157	
Total Results		122	178	300	

Relative Sensitivity: 98% Relative Specificity: 87% Accuracy: 91%

When compared to GC/MS at 25 ng/mL, the following results were tabulated:

Method THC One Results		GC/MS		Total	
		Positive	Negative	Results	
Step	Positive	137	6	143	
Test Device	Negative	4	153	157	
Total Re	sults	141	159	300	

Relative Sensitivity: 97% Relative Specificity: 96% Accuracy: 97%

Point of Care Accuracy

A study was conducted using the same clinical specimens with ten percent (10%) distribution at 25% above and below the 50ng/mL cut-off at three geographically distinct point of care sites to determine the accuracy of the One Step Marijuana Test Device in the hands of point of care user. Forty (40) positive specimens and forty (40) negative specimens were tested on three (3) different lots of each product. The difference in sensitivity and specificity results obtained by the laboratory

The difference in sensitivity and specificity results obtained by the laboratory professional for the same clinical specimens compared to the results obtained by the point of care (untrained) user was insignificant. At a ninety-five percent (95%) confidence interval, the odds ratio for the point of care user versus the laboratory professional was 1 to 1 for sensitivity and specificity.

Analytical Sensitivity

A drug-free urine pool was spiked with 11-nor- Δ 9-Tetrahytrocannabinol-9-carboxylic acid at the following concentrations: 75 ng/ml, 62.5 ng/ml, 37.5 ng/ml, 25 ng/ml, and 0 ng/ml. The result demonstrates 100% accuracy at 50% above and 50% below the cut-off concentration. The data are summarized below:

THC Concentration	Percent Of	,	Visua	l Result
(ng/mL)	Cutoff	n	Negative	Positive
0	0	30	30	0
25	50%	30	30	0
37.5	75%	30	10	20
50	Cutoff	30	4	26

62.5	125%	30	3	27
75	150%	30	0	30

Specificity

The following table lists compounds and their respective concentrations in urine that yield a positive result in the THC One Step Marijuana Test Device at 5 minutes.

Compound	Concentration (ng/mL)		
Cannabinol	20,000		
11-nor-Å -THC-9 COOH	30		
11-nor-♂-THC-9 COOH	50		
Å [™] THC	15,000		
₿-THC	15,000		

Precision

A study was conducted at 3 physician's offices by untrained operators using 3 different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens containing, according to GC/MS, no THC, 25% THC above and below the cut-off and 50% THC above and below the 50 ng/mL cut-off was provided to each site. For the specimens below the -25 % cut-off concentration, the 3 sites demonstrated 98% agreement with each other. For the -25% to +25% cut-off specimens, the 3 sites demonstrated 83% agreement with each other. For specimens above the +25% cut-off concentration, the 3 sites demonstrated 100% agreement with each other. For all results, the 3 sites were found to have a 92% agreement with each other.

Effect of Urinary Specific Gravity

Twenty-six (26) urine samples of normal, high, and low specific gravity ranges were spiked with 25 ng/ml and 75 ng/ml of 11-nor-Δ9-Tetrahytrocannabinol-9-carboxylic acid, respectively. The One Step Marijuana Test Device was tested in duplicate using the twenty-six neat and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity does not affect the test results.

Effect of the Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with 11-nor-Δ9-Tetrahytrocannabinol-9-carboxylic to 25 ng/ml and 75 ng/ml. The spiked, pH-adjusted urine was tested with the THC One Step Marijuana Test Device in duplicate and interpreted according to the package insert. The results demonstrate that varying ranges of pH does not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in urine not associated with THC. The following compounds show no cross-reactivity when tested with the THC One Step Marijuana Test Device at a concentration of $100~\mu g/mL$:

Non Cross-Reacting Compounds

rion cross reacting compounds					
4-Acetamidophenol	Fenoprofen	Pentazocine			
Acetophenetidin	Furosemide	Pentobarbital			
N-Acetylprocainamide	Gentisic acid	Perphenazine			
Acetylsalicylic acid	Hemoglobin	Phencyclidine			
Aminopyrine	Hydralazine	Phenelzine			
Amitryptyline	Hydrochlorothiazide	Phenobarbital			
Amobarbital	Hydrocodone	Phentermine			
Amoxicillin	Hydrocortisone	L-Phenylephrine			
Ampicillin	O-Hydroxyhippuric acid	β-Phenylethlamine			
Ascorbic acid	3-Hydroxytyramine	β-Phenyllethylamine			
D,L-Amphetamine	Ibuprofen	Phenylpropanolamine			

Prednisolone L-Amphetamine Imipramine Apomorphine Iproniazid Prednisone (-) Isoproterenol Procaine Aspartame Atropine Isoxsuprine Promazine Benzilic acid Ketamine Promethazine Benzoic acid Ketoprofen D,L-Propanolol Benzovlecgonine Labetalol D-Propoxyphene Benzphetamine D-Pseudoephedrine Levorphanol Bilirubin Loperamide Quinidine Maprotiline Ouinine Brompheniramine Caffeine Meprobamate Ranitidine Cannabidiol Methadone Salicylic acid Chloralhydrate Methoxyphenamine Secobarbital Chloramphenicol (+) 3,4-Methylenedioxy-Serotonin (5-Chlordiazepoxide amphetamine Hydroxytyramine) Chlorothiazide (+) 3,4-Methylenedioxy-Sulfamethazine (±) Chlorpheniramine methamphetamine Sulindac Chlorpromazine Methylphenidate Temazepam Chlorquine Methyprylon Tetracvcline Cholesterol Morphine-3-β-D-Tetrahydrocortisone, 3 Clomipramine glucuronide Acetate Clonidine Nalidixic acid Tetrahydrocortisone 3 (B-D Cocaine hydrochloride Nalorphine glucuronide) Codeine Naloxone Tetrahydrozoline Cortisone Naltrexone Thebaine (-) Cotinine Thiamine Naproxen Creatinine Niacinamide Thioridazine Deoxycorticosterone Nifedipine D, L-Thyroxine Dextromethorphan Norcodein Tolbutamine Diazepam Norethindrone Triamterene Diclofenac D-Norpropoxyphene Trifluoperazine Diflunisal Noscapine Trimethoprim Digoxin D,L-Octopamine Trimipramine Diphenhydramine Oxalic acid Tryptamine Doxylamine Oxazepam D, L-Tryptophan Ecgonine hydrochloride Oxolinic acid Tyramine Ecgonine methylester Oxycodone PrD, L-Tyrosine (-) Y Ephedrine Oxymetazoline Uric acid Erythromycin Verapamil p-Hydroxy**β-Estradiol** methamphetamine Zomepirac Estrone-3-sulfate Papaverine Ethyl-p-aminobenzoate Penicillin-G

BIBLIOGRAPHY

- 1. Hawks RL, CN Chiang. *Urine Testing for Drugs of Abuse*. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986
- Baselt RC. <u>Disposition of Toxic Drugs and Chemicals in Man.</u> 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488

Printed in China DN: R015454-04

Eff. Date: 2002-12-18